A turmeric study published in Cancer Letters is paving the way for a revolution in the way that we both understand and treat cancer

Titled, “Targeting cancer stem cells by curcumin and clinical applications,” U.S. researchers evaluated the primary polyphenol in the Indian spice known as curcumin for its ability to target cancer stem cells (CSCs), which are believed to be at the root cause of tumor formation and malignancy.

Whereas conventional models of cancer assumed that the majority of the cancer cells within a tumor possess self-renewal capacity to differing degrees, the CSC model proposes that, “[T]he initiation, maintenance, and growth of a tumor is driven by a minor population of cancer cells termed cancer stem cells (CSCs),” and that “These CSCs undergo continuous self-renewal and differentiate to heterogeneous cancer cells, yielding new tumors recapitulating the parental tumors, while the majority of cancer cells lack self-renewal capacity.”

In other words, the CSCs are at the apex of a hierarchy of cells within the tumor, and are the “mother” of the various daughter cells that make it up, most of which are intrinsically benign. In the study, conventional treatment with chemotherapy and radiotherapy (as tested by a rodent model with a 2-year experimental window to evaluate treatment efficacy and safety) was found incapable of identifiying the CSC-mediated cause of post-treatment tumor recurrence, which in humans can take decades after initial treatment to manifest. Although it was possible to debulk a tumor with surgery, chemotherapy and radiation, CSC populations were often missed or even enriched as a result. When the tumor mass regrew it often became more invasive and treatment-resistant, resulting in the rapid demise and death of the patient — deaths which are often written off inaccurately or disingenuously as non-treatment related.

Given that conventional treatment can drive an intrinsically benign tumor (i.e., so-called indolent tumors) into greater invasiveness through increasing the number of intrinsically resilient cancer stem cells at the very same moment that it kills the less or non-harmful daughter cells, alternative treatment approaches are needed now more than ever.

The Cancer Stem Cell Killing Role of Turmeric (Curcumin)

Turmeric and curcumin extract have been extensively studied for their ability to kill various cancer cell lines. In fact, the literature is so abundant that it is both surprising and disheartening that so many patients who are in need of safe, effective and affordable treatments are not being given information about it.

The study identified a number of ways in which curcumin provides an ideal CSC-targeting therapy, including:

• Regulation of the CSC self-renewal pathway:  curcumin appears to directly and indirectly influence at least three self-renewal pathways within cancer stem cells, namely, Wnt/b-catenin, sonic hedgehog 89 (SHH), and Notch. The authors list 12 difference cancer cell lines which curcumin appear to affect positively.
• Modulation of microRNA: microRNAs are short non-coding RNA sequences that regulate approximately 33% of the protein-coding genes in the human genome. They bind to target messenger RNAs (mRNAs) leading to their degradation or inactivation. Curcumin has been found to alter the expression of microRNAs in cancer stem cells in a way that would suggest a strong suppression of tumor formation.
• Direct anti-cancer activity: Curcumin exhibits the ability to selectively kill cancer cells versus healthy cells and synergizes with conventional chemotherapy agents making them more effective (in some cases less harmful).

The researchers evaluated the safety and tolerability of all the available human research on curcumin in human cancer studies and found no cause for concern. They also noted “Curcumin, as a natural remedy for thousands of years, has been shown to be well tolerated and causes no significant toxicity in a number of clinical trials.”

The conclusion of the study:

“Curcumin, as well as its modified forms (analogues or nanoparticle-encapsulated formulations), has shown great potential to inhibit CSCs in several types of cancer both in cell cultures and in mouse models, including glioma, breast, colorectal, pancreatic, brain, and esophageal cancers. Some analogues (e.g., CDF) and formulations (e.g., nanotechnology-based formulation) have exhibited improved efficacy against CSC-like cells and greater growth-inhibitory capacity in tumors. It is promising to evaluate curcumin and its modified forms in other types of CSCs.”

Republished from GreenMedInfo.com